Zentek (CVE:ZEN) Shares Cross Below 200 Day Moving Average - Should You Sell?

Key Points

• Zentek shares crossed below its 200-day moving average, trading as low as C$0.75 versus a 200-day MA of C$1.04 on volume of 22,147 shares.
• The company has a market cap of C$80.66 million, a negative P/E (−9.38) and a very high debt-to-equity ratio (15.41), indicating losses and elevated leverage.
• Zentek develops graphene-based products—including ZenGUARD antimicrobial coatings, surgical masks, HVAC filters and diagnostics—and holds the Albany graphite project in Northern Ontario.

Zentek Ltd. (CVE:ZEN - ) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$1.04 and traded as low as C$0.75. Zentek shares last traded at C$0.75, with a volume of 22,147 shares traded.

Zentek Stock Performance

The business has a 50-day moving average of C$0.90 and a two-hundred day moving average of C$1.04. The company has a debt-to-equity ratio of 15.41, a current ratio of 1.00 and a quick ratio of 7.59. The company has a market cap of C$80.66 million, a P/E ratio of -9.38 and a beta of 0.22.

Zentek Company Profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.